Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
This is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of patients with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh ... Read moreThis is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of patients with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh A). This is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Testing Prior to the Initiation of Therapy: Test all patients for HBV infection by measuring HBsAg and anti-HBc.Recommended dosage: Three tablets (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg) taken orally once daily with food.See recommended treatment duration in tables below-Treatment-Naïve Patients: HCV Genotype 1, 2, 3, 4, 5, or 6 No Cirrhosis: 8 weeks Compensated Cirrhosis (Child-Pugh A): 12 weeks Treatment-Experienced Patients: HCV Genotype 1 Patients Previously Treated With a Regimen Containing: An NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor No Cirrhosis: 16 weeks Compensated Cirrhosis (Child-Pugh A): 16 weeks Treatment-Experienced Patients: HCV Genotype 1 Patients Previously Treated With a Regimen Containing: An NS3/4A PI without prior treatment with an NS5A inhibitor No Cirrhosis: 12 weeks Compensated Cirrhosis (Child-Pugh A): 12 weeks Treatment-Experienced Patients: HCV Genotype 1, 2, 4, 5 or 6 Patients Previously Treated With a Regimen Containing: PRS No Cirrhosis: 8 weeks Compensated Cirrhosis (Child-Pugh A): 12 weeks Treatment-Experienced Patients: HCV Genotype 3 Patients Previously Treated With a Regimen Containing: PRS No Cirrhosis: 16 weeks Compensated Cirrhosis (Child-Pugh A): 16 weeks
Side Effects
In subjects receiving Mavixen, the most commonly reported adverse reactions (greater than 10%) are headache and fatigue.
Cautions & Contraindications
Warnings & Precautions
Risk of Hepatitis B Virus Reactivation: Test all patients for evidence of current or prior HBV infection before initiation of HCV treatment. Monitor HCV/HBV coinfected patients for HBV reactivation and hepatitis flare during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.
Contraindications
Patients with severe hepatic impairment (Child-Pugh C). Coadministration with atazanavir and rifampin